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The hypoglycemic effects after oral administration of
vanadium have been studied previously in many species
such as rats, mice and even humans. However, there has
been no prior report on the glucose lowering effect of
vanadium on diabetic dogs. Therefore, the purpose of this
study was to evaluate the hypoglycemic effects of oral
vanadium on diabetic dogs. Diabetes mellitus in the dogs
studied was induced by alloxan monohydrate intravenous
injection. The dogs were divided into two groups, one was
the diabetic control (DC) group (n = 4) and the other was
the vanadium treated (DV) group (n = 6). Fresh water was
supplied to the dogs in the DC group, but sodium
metavanadate solution (0.1~0.2 mg/ml) was given to the
dogs in DV group from one week after the alloxan
injection. The fasting glucose levels, fructosamine and
serum chemistry profiles were compared between the two
groups weekly for three weeks. The fasting blood glucose
levels in DV group were significantly lower than those in
the DC group (p < 0.01). Fructosamine levels in the DV
group were also lower than those in the DC group (p <
0.05). The serum chemistry profiles were not significantly
different in comparisons between the two groups.
However, the cholesterol levels were significantly lower in
the DV group compared to the DC group (p < 0.05). Our
findings showed that oral vanadium administration had a
hypoglycemic effect on chemically induced diabetic dogs.
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Introduction
Diabetes mellitus is one of the most common endocrine
diseases in dogs. Type I or insulin-dependent diabetes
mellitus (IDDM) is caused by the lack of insulin and results
from the destruction of the insulin-producing beta cells in
the pancreas [8]. The present treatment for IDDM includes
careful monitoring of blood glucose levels, multiple injections
of insulin, specialized diet and an exercise regimen.
Vanadium is a transitional element that is widely distributed
in nature, with an atomic number of 23, atomic weight
50.9415 and oxidation states from 3+ to 5+. Its function in
the body is not well understood. However, orally administrated
sodium vanadate has been reported to improve DM in
human diabetes before the discovery of insulin and its
clinical use to treat DM has been previously demonstrated
[3]. Vanadium compounds have been shown to be effective
in animal models such as spontaneously diabetic (BB) rats,
insulin-resistant Zucker fa/fa rats [4] and recently in human
trials [3]. In addition, sodium vanadate has been proven a
valuable adjunct to insulin in the treatment of diabetes
mellitus [3,4].
The mechanism by which lowering of the blood glucose
levels occurs is not understood. Evidence exists that the
insulin-like actions of vanadate involve phosphorylation of
the insulin receptor [12]. It has been suggested that the
glucose-lowering effect of vanadium is due to its insulin-
mimetic properties, such as increasing glucose transport [7],
glycogen synthesis, glycolysis [6] and glucose oxidation in
adipose tissue [6,10]. Moreover, vanadium has been reported
to stimulate lipogenesis [11].
There are no prior reports on the glucose lowering effects
of vanadium in diabetic dogs. Therefore, the purpose of this
study was to assess the effects of treatment of vanadium
salts in alloxan-induced diabetic dogs by comparing the
blood glucose levels and serum chemistry profiles between
a diabetic control group and a vanadium treatment group.
Materials and Methods
Preparation of experimental dogs
Clinically normal adult mongrel dogs without distinction
of breed and sex were prepared for this experiment. Their
body weight ranged from 2 to 6 kg initially. They were
supplied dry food for adult dogs twice a day during this
study, and given free access to sufficient tap water before the
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vanadium treatment study. They were adjusted to the new
experimental environment adequately before the induction
of diabetes mellitus.
Induction of diabetes mellitus
The dogs were fasted for 24 h prior to the induction of
diabetes mellitus. Blood was collected for baseline data
determination including: baseline glucose, fructosamine and
serum chemistry profile (BUN, creatinine, ALT, AST, ALP,
TG, cholesterol, electrolytes). Catheters were placed in the
cephalic or jugular veins and a lactated Ringer’s solution
was infused at a maintenance dose.
Fresh solution of alloxan monohydrate (Sigma, USA) for
diabetes mellitus induction was prepared just prior to
injection [1,2]. Alloxan solution was made by dissolving it
in normal saline at a concentration of 100 mg/ml, and
filtered using a 0.22 µm syringe filter unit (MILLEX -GV,
0.22 µm syringe filter unit; Millipore SA, France). This
prepared solution was given intravenously at a dose of
80~100 mg/kg of alloxan for the dogs immediately after
preparation. Six hours after alloxan injection, the blood
glucose levels were measured every 4 h until resolution of
the hypoglycemia. If the blood glucose levels were too low,
a glucose solution (5-10%) was given intravenously.
Selection of diabetic dogs
After injection of the alloxan solution, the blood glucose
levels were measured frequently for days. Once the
hypoglycemia resolved the fasting blood glucose levels
were measured at 10 : 00 a.m. every morning. The dogs
were evaluated for glycosuria once a day during the first
stage. Diabetes was confirmed at one week after the alloxan
injection by the presence of continuous fasting hyperglycemia
(fasting blood glucose level >180 mg/dl) and persistent
glycosuria. Only the dogs with induced diabetes mellitus
and without acute renal failure or any other side effects were
selected to continue the experiment. 
Experimental design and oral administration of sodium
metavanadate solution
The selected diabetic dogs were divided into two groups
by random assignment. . First, a diabetic control group (DC
group, n = 4), was given normal adult dry pellets and tap
water. The vanadium treatment group (DV group, n = 6) of
diabetic dogs was treated with vanadium (96% sodium
metavanadate; Acros Organics, USA). They were supplied
the same dry pellets and housed in the same environment as
the DC control group; however, the dogs in this group were
given 0.1~0.2 mg/ml (w/v) of sodium metavanadate solution
to drink for three weeks instead of tap water. All dogs had
free access to the vanadium solution and water.
The sodium metavanadate solution was prepared by
dissolving it in purified water. Alloxan-treated dogs were
given aqueous solutions of sodium metavanadate beginning
one week after the confirmation of diabetes mellitus, and
this continued to be supplied for three weeks.
Blood samples were collected from the jugular vein every
week before and after alloxan injection and vanadium
administration for four weeks. The BUN, creatinine, ALT,
AST, ALP, triglyceride, cholesterol and electrolytes were
measured. They were analyzed using an automatic serum
chemical analyzer (VetTest 8008; IDEXX Lab, USA) and
automatic electrolytic analyzer (VetLyte; IDEXX Lab,
USA). Fructosamine levels were also determined.
Pathological findings
After death or euthanasia, one dog in each group was selected
for necropsy. In addition, one normal dog was sacrificed for
necropsy to compare the DC and DV groups. The internal
organs such as pancreas, kidney, liver were fixed in formalin
solution and stained with H&E and then examined for the
microscopic morphology.
Statistical methods
All data were expressed as means and standard deviation
(SD). Statistical differences between the DC group and the
DV group were determined by the Student’s t-test.
Results
The fasting blood glucose levels and fructosamine levels
were measured every week. The former are presented in Fig.
1, and the latter are shown in Fig. 2. As the data shows, the
blood glucose levels of both groups were within normal
range before the injection of alloxan, however it increased
after one week from the onset of the injections, and
remained high. With the maintained hyperglycemia, the
dogs showed polyuria, polydipsia, polyphagia, glycosuria
and weight loss; although the clinical signs related to the
diabetes mellitus were not obvious. Therefore, the induced
diabetes mellitus was confirmed by the continuous
hyperglycemia, glycosuria and clinical signs.
The blood glucose levels in the DV group were significantly
lower compared to the DC group at 2, 3 and 4 weeks after
the injection of the alloxan (p < 0.01). The fructosamine
levels showed a similar pattern to the blood glucose levels in
both groups. The fructosamine levels of the DV group were
also significantly lower than those of the DC group at 2, 3
and 4 weeks (p < 0.05). In addition, for the dogs in the DV
group, the food and water intake were decreased and the
volume of urine decreased compared to the dogs in the DC
group, although the exact data were not obtained.
Selected chemical parameters during the one month study
following alloxan administration are summarized in Table 1.
The serum chemistry profiles were not significantly different
in comparisons between the two groups, except for the
cholesterol levels. The cholesterol levels in the DV group
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0.05). This may have been caused by the low blood glucose
levels in the DV group causing normalization of lipid
metabolism.
Necropsy was performed after euthanasia, or death in one
dog, in the individual group and in one normal dog. The
pancreas was examined mainly, especially the pancreatic
islets. The histopathology examination showed that pancreatic
islets disappeared and that the exocrine tissue remained
relatively unaffected; any remaining islets were considerably
atrophied compared to the normal pancreas (Fig. 3). These
findings indirectly show that the blood glucose levels in the
DV group may have been lowered not by insulin but by
vanadium; this is because almost all of the pancreatic islet
beta cells were destroyed and therefore resulted in insulin
deficiency. The kidneys and livers were also examined.
Necrosis of epithelial cells was observed in the tubules
around the glomerulus of the kidney and glycogen
degeneration was observed in the hepatic cells of both
groups (data not shown). The damage to the kidneys may
have been due to the alloxan, and glycogen accumulation in
the hepatic cells may have been caused by the diabetic
condition.
Fig. 1. The blood glucose levels of the vanadium treatment (DV)
groups were significantly lower than those of diabetic control
(DC) group. *Significantly different compared to control group
as p <0 . 0 1 .
Fig. 2. The fructosamine levels of the vanadium treatment (DV)
groups were significantly lower than those of the diabetic control
(DC) group. * Significantly different compared to control group
as p <0 .  0 5 .
Table 1. Serum chemistry profiles
0 wk 1 wk 2 wks 3 wks 4 wks
BUN
(mg/dl)
DC 18.0 ± 4.97 31.8 ± 16.5 23.3 ± 11.0 34.8 ± 26.5 25.3 ± 9.32
DV 25.0 ± 4.77 37.3 ± 14.7 22.5 ± 6.57 21.5 ± 3.67 21.8 ± 8.78
Creatinine
(mg/dl)
DC 0.95 ± 0.11 1.21 ± 0.53 0.93 ± 0.12 0.22 ± 0.47 0.89 ± 0.39
DV 0.82 ± 0.14 1.07 ± 0.35 0.79 ± 0.21 0.63 ± 1.03 0.56 ± 0.15
ALT
(IU/l)
DC 100 ± 60.0 58.8 ± 43.4 52.0 ± 42.7 158 ± 192 83.0 ± 43.1
DV 38.7 ± 34.4 30.7 ± 12.1 30.2 ± 9.85 31.7 ± 14.4 43.3 ± 25.2
AST
(IU/l)
DC 12.3 ± 15.8 24.8 ± 10.7 35.5 ± 3.70 55.5 ± 45.9 27.8 ± 6.50
DV 27.8 ± 15.0 22.2 ± 5.31 25.7 ± 6.77 25.7 ± 14.0 20.8 ± 6.18
ALP
(IU/l)
DC 105 ± 23.1 101 ± 38.9 193 ± 162 268 ± 212 165 ± 122
DV 147 ± 25.7 259 ± 164 147 ± 41.2 123 ± 53.2 89.2 ± 46.3
TG
(mg/dl)
DC 54.8 ± 22.6 74.5 ± 9.88 87.0 ± 15.4 113 ± 52.8 101 ± 50.1
DV 84.2 ± 47.6 82.8 ± 63.1 84.7 ± 47.8 62.8 ± 12.3 71.7 ± 13.2
Cholesterol
(mg/dl)
DC 151 ± 33.0 192 ± 50.5 248 ± 37.1 302 ± 120 280 ± 100
DV 175 ± 33.1 225 ± 53.6 181 ± 21.8 174 ± 23.3 163 ± 31.4
Na
(mEq/l)
DC 157 ± 8.18 152 ± 5.19 152 ± 3.56 156 ± 8.92 150 ± 4.03
DV 151 ± 3.14 148 ± 4.68 148 ± 3.44 150 ± 6.98 150 ± 7.74
K
(mEq/l)
DC 5.05 ± 0.55 5.03 ± 0.66 4.52 ± 0.24 5.55 ± 1.17 5.17 ± 0.66
DV 4.88 ± 0.40 4.67 ± 0.58 4.97 ± 0.36 5.15 ± 0.45 5.07 ± 0.33
Cl
(mEq/l)
DC 118 ± 7.05 113 ± 4.50 114 ± 2.16 116 ± 4.50 113 ± 3.77
DV 115 ± 2.48 110 ± 3.41 115 ± 3.78 118 ± 3.06 118 ± 4.69394 Joo-Min Kim et al.
Discussion
The results of this investigation demonstrated that
administration of a single dose of alloxan to dogs produced a
reproducible model of diabetes mellitus that had minimal
beta cell activity, and elevated glucose and cholesterol levels.
However, the high mortality among the experimental dogs
and the evidence of toxicity to the kidney and liver in
addition to the pancreas was a serious problem. Many of the
dogs developed symptoms such as emesis, hypersalivation,
diarrhea or soft stool even without azotemia. The hypoglycemia
6 h after injection caused extremely adverse effects, perhaps
related to severe beta-cell destruction. The extent of DM
induction was variable. This might indicate that susceptibility
of dogs to the beta-cytotoxic effects of systemic alloxan
administration varies. In this experiment, the lactated ringer’s
solution was infused for a prehydration maintenance dose
before the injection of the alloxan solution. It likely led to
fluid diuresis by enhancing renal perfusion and resulted in a
reduced renal toxicity from the alloxan.
The mechanism explaining the hypoglycemic effects of
vanadium is not well understood; however, several hypotheses
have been proposed. Because vanadium behaves like phosphate,
the biochemistry of vanadium has been shown to inhibit
protein phosphotyrosine phosphatase, which in turn stimulates
protein tyrosine phosphorylation [12]. Thus, vanadium activated
autophosphorylation of solublized insulin receptors similar
to insulin action. Vanadium also stimulated the tyrosine
kinase activity of the insulin receptor beta subunit. In
addition, both vanadate and vanadyl have been found to be
effective in stimulating glucose metabolism in rat adipocytes
[4]. The concentration of vanadium solution was chosen
based on a previous report that demonstrated a pronounced
glucose-lowing effect in STZ-diabetic rats [11]. During
administration, side effects were observed in many of the
vanadium treated diabetic dogs. These dogs showed symptoms
of lethargy, weight loss, mucous and/or hemorrhagic
diarrhea, and refusal to eat and drink, especially during the
first stage when vanadium water was provided for drinking.
Seven dogs died or were sacrificed after drinking the
vanadium water without renal dysfunction (normal BUN/
Creatinine, normal production of urine); we thought that
vanadium toxicity may have played a role, although this was
not confirmed. These dogs were excluded from the study.
All other vanadium treated dogs were healthy and tolerated
the vanadium drinking water; their GI signs resolved
progressively, without overt indication of toxicity during the
three week treatment period. Moreover, the vanadium
treatment did not significantly elevate the BUN, creatinine,
ALT, AST, ALP levels in the DV group.
The most serious problem of the vanadium was its side
effects. However, new compounds of vanadium are under
development. These new compounds will be able to potentiate
insulin-like effects with decreased undesirable side effects.
Once these problems are resolved further use of this compound
may become more clinically relevant for research and
treatment of diabetes mellitus.
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